Grants paid by The Maren Foundation
EIN 81-4295288 · Darien, CT · Form 990-PF, Part XV · NTEE H80
The Maren Foundation of Darien, CT (EIN 81-4295288) reported 5 grants paid totaling $115,000 to 2 recipients in tax years 2020–2024, on Form 990-PF, Part XV. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$115,000
5 grants
Recipients
2
distinct organizations
Tax years
2020–2024
4 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2020 | 2 | $90,000 | — |
| 2022 | 1 | $15,000 | — |
| 2023 | 1 | $5,000 | — |
| 2024 | 1 | $5,000 | — |
Top recipients
The 2 recipients receiving the most from The Maren Foundation, by grants paid, out of 2 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Johns Hopkins University Department of Medicine | U | Baltimore, MD | 4 | $75,000 | 2024 |
| University of Munster | U | Munster | 1 | $40,000 | 2020 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 5 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Johns Hopkins University Department of Medicine Baltimore, MD | U | $5,000 | paid | The ongoing research investigates whether Vitamin D replacement:1)Helps reduce risk factors for Cardiovascular disease, namely hypertension and high cholesterol.2)Reduces blood clots, such as stroke and deep vein thrombosis.The Hopkins Lupus Cohort is a thirty year longitudinal cohort in which patients are followed by protocol every three months, with over 80,000 clinical visits from more than 2600 individual patients in the cohort database.This quantity of data makes it possible identify risk factors for outcomes, such as cardiovascular events and thrombosis (blood clots) and to tease out the relative importance of disease activity, exposure to corticosteroids, and low vitamin D as risk factors for these events. The research results would help lupus because vitamin D would reduce potentially two of the three main risk factors (lupus activity and traditional cardiovascular risk factors)that contribute to the excess risk of cardiovascular disease in SLE. | 202523219349102332 |
| 2023 | Johns Hopkins University Department of Medicine Baltimore, MD | U | $5,000 | paid | The ongoing research investigates whether Vitamin D replacement:1)Helps reduce risk factors for Cardiovascular disease, namely hypertension and high cholesterol.2)Reduces blood clots, such as stroke and deep vein thrombosis.The Hopkins Lupus Cohort is a thirty year longitudinal cohort in which patients are followed by protocol every three months, with over 80,000 clinical visits from more than 2600 individual patients in the cohort database.This quantity of data makes it possible identify risk factors for outcomes, such as cardiovascular events and thrombosis (blood clots) and to tease out the relative importance of disease activity, exposure to corticosteroids, and low vitamin D as risk factors for these events. The research results would help lupus because vitamin D would reduce potentially two of the three main risk factors (lupus activity and traditional cardiovascular risk factors)that contribute to the excess risk of cardiovascular disease in SLE. | 202403179349101320 |
| 2022 | Johns Hopkins University Department of Medicine Baltimore, MD | U | $15,000 | paid | The ongoing research investigates whether Vitamin D replacement:1)Helps reduce risk factors for Cardiovascular disease, namely hypertension and high cholesterol.2)Reduces blood clots, such as stroke and deep vein thrombosis.The Hopkins Lupus Cohort is a thirty year longitudinal cohort in which patients are followed by protocol every three months, with over 80,000 clinical visits from more than 2600 individual patients in the cohort database.This quantity of data makes it possible identify risk factors for outcomes, such as cardiovascular events and thrombosis (blood clots) and to tease out the relative importance of disease activity, exposure to corticosteroids, and low vitamin D as risk factors for these events. The research results would help lupus because vitamin D would reduce potentially two of the three main risk factors (lupus activity and traditional cardiovascular risk factors)that contribute to the excess risk of cardiovascular disease in SLE. | 202343199349102789 |
| 2020 | Johns Hopkins University Department of Medicine Baltimore, MD | U | $50,000 | paid | The ongoing research investigates whether Vitamin D replacement:1)Helps reduce risk factors for Cardiovascular disease, namely hypertension and high cholesterol.2)Reduces blood clots, such as stroke and deep vein thrombosis.The Hopkins Lupus Cohort is a thirty year longitudinal cohort in which patients are followed by protocol every three months, with over 80,000 clinical visits from more than 2600 individual patients in the cohort database.This quantity of data makes it possible identify risk factors for outcomes, such as cardiovascular events and thrombosis (blood clots) and to tease out the relative importance of disease activity, exposure to corticosteroids, and low vitamin D as risk factors for these events. The research results would help lupus because vitamin D would reduce potentially two of the three main risk factors (lupus activity and traditional cardiovascular risk factors)that contribute to the excess risk of cardiovascular disease in SLE. | 202201459349100210 |
| 2020 | University of Munster Munster | U | $40,000 | paid | To study the influence of dietary resistant starch content on the gut microbiota of patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Results available upon request. | 202201459349100210 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990PF | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202523219349102332 |
| 990PF | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202403179349101320 |
| 990PF | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202343199349102789 |
| 990PF | 2020 | 2020-12-31 | not stated | 2020v4.2 | 202201459349100210 |
Derived from IRS Form 990-PF e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/814295288.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.